Search results
Author(s):
Massimiliano Camilli
,
Luca Maggio
,
Lorenzo Tinti
,
et al
Added:
3 months ago
Author(s):
Harriette Van Spall
,
Isabelle Mahé
Added:
3 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Author(s):
Yugo Yamashita
Added:
1 year ago
ESC 23 — In this concise interview, Dr Yugo Yamashita (Kyoto University Graduate School of Medicine, JP) reveals the findings of the ONCO DVT Study (NCT03895502).
The ONCO DVT study (Takeshi Morimoto) aimed to determine the ideal duration of anticoagulation therapy with the direct oral anticoagulant (DOAC) edoxaban for the treatment of isolated distal deep vein thrombosis (IDDVT) in patients…
View more
ACC.24: The PROACT Trial
Author(s):
David Austin
Added:
1 year ago
Video
UCLH Cancer Academy
Supplier
Lawrence N. Shulman
Job title: Deputy Director
Author
Mark Linch
Job title: Associate Professor and Consultant in Uro-Oncology
Author
Alicia Okines
Research Area(s) / Expertise:
Job title: Consultant Medical Oncologist, Royal Marsden Hospital, London, UK
Author
Randall A. Oyer
Research Area(s) / Expertise:
Job title: Medical Director, Ann B. Barhshinger Cancer Institute, Lancaster General Hospital, University of Pennsylvania, US
Author
Isabelle Mahé
Research Area(s) / Expertise:
Job title: Professor of Internal Medicine
Author